March 31, 2022 07:04 AM EDT
FDA+

Af­ter an RTF and some stern warn­ings, FDA slaps Cy­to­Dyn with two clin­i­cal holds

Amber Tong

Cy­to­Dyn’s col­or­ful and in­fa­mous CEO may be gone, but the is­sues that be­gan fes­ter­ing dur­ing his long reign are very much here to stay. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

Leg­end to dou­ble Carvyk­ti pro­duc­tion as it tar­gets block­buster sta­tus 

In­sil­i­co nabs $110M Se­ries E for AI drug dis­cov­ery af­ter stalling Hong Kong IPO plans

As­cle­tis’ not-so-great weight loss da­ta; Vi­vace’s $35M Se­ries D

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times